We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Editas Medicine (EDIT - Free Report) . Shares have added about 6.2% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Editas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Editas incurred a loss of 15 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 63 cents per share in the year-ago quarter.
Collaboration and other research and development revenues totaled approximately $11.9 million, comfortably surpassing the Zacks Consensus Estimate of $2 million. Revenues were $3.6 million in the year-ago quarter. The increase reflected deferred revenues recognized following the expiration of certain rights under the company’s collaboration with Bristol Myers.
EDIT’s Q2 Results in Detail
Research and development expenses increased 25% year over year to $20.2 million in the second quarter of 2026. The increase was primarily related to higher external expenses supporting ongoing research and preclinical work for EDIT-401.
General and administrative expenses declined 10% to $11.6 million from $12.9 million in the year-ago quarter. The decrease was due to lower employee-related expenses and reduced professional services costs following the workforce reduction and discontinuation of the reni-cel program.
Editas Benefits From Restructuring Adjustments
Editas recorded a restructuring and impairment benefit of $1.3 million in the reported quarter. This compared favorably with restructuring and impairment charges of $26.1 million in the second quarter of 2025.
The benefit reflected favorable adjustments to previously estimated contract costs associated with the discontinuation of the reni-cel program.
Editas had cash, cash equivalents and investments worth $211.6 million as of June 30, 2026, compared with $123.6 million as of March 31, 2026. The company expects its existing cash position to fund operating and capital needs into the second half of 2028.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
The consensus estimate has shifted 33.55% due to these changes.
VGM Scores
At this time, Editas has a average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock has a grade of F on the value side, putting it in the bottom 20% quintile for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Editas belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Harmony Biosciences Holdings, Inc. (HRMY - Free Report) , has gained 8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Harmony Biosciences reported revenues of $261.28 million in the last reported quarter, representing a year-over-year change of +30.3%. EPS of $1.28 for the same period compares with $0.68 a year ago.
Harmony Biosciences is expected to post earnings of $1.03 per share for the current quarter, representing a year-over-year change of +18.4%. Over the last 30 days, the Zacks Consensus Estimate has changed +1.5%.
Harmony Biosciences has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.
View the Zacks #1 Rank List
Image: Bigstock
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Editas Medicine (EDIT - Free Report) . Shares have added about 6.2% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Editas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Editas incurred a loss of 15 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 63 cents per share in the year-ago quarter.
Collaboration and other research and development revenues totaled approximately $11.9 million, comfortably surpassing the Zacks Consensus Estimate of $2 million. Revenues were $3.6 million in the year-ago quarter. The increase reflected deferred revenues recognized following the expiration of certain rights under the company’s collaboration with Bristol Myers.
EDIT’s Q2 Results in Detail
Research and development expenses increased 25% year over year to $20.2 million in the second quarter of 2026. The increase was primarily related to higher external expenses supporting ongoing research and preclinical work for EDIT-401.
General and administrative expenses declined 10% to $11.6 million from $12.9 million in the year-ago quarter. The decrease was due to lower employee-related expenses and reduced professional services costs following the workforce reduction and discontinuation of the reni-cel program.
Editas Benefits From Restructuring Adjustments
Editas recorded a restructuring and impairment benefit of $1.3 million in the reported quarter. This compared favorably with restructuring and impairment charges of $26.1 million in the second quarter of 2025.
The benefit reflected favorable adjustments to previously estimated contract costs associated with the discontinuation of the reni-cel program.
Editas had cash, cash equivalents and investments worth $211.6 million as of June 30, 2026, compared with $123.6 million as of March 31, 2026. The company expects its existing cash position to fund operating and capital needs into the second half of 2028.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
The consensus estimate has shifted 33.55% due to these changes.
VGM Scores
At this time, Editas has a average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock has a grade of F on the value side, putting it in the bottom 20% quintile for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Editas belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Harmony Biosciences Holdings, Inc. (HRMY - Free Report) , has gained 8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Harmony Biosciences reported revenues of $261.28 million in the last reported quarter, representing a year-over-year change of +30.3%. EPS of $1.28 for the same period compares with $0.68 a year ago.
Harmony Biosciences is expected to post earnings of $1.03 per share for the current quarter, representing a year-over-year change of +18.4%. Over the last 30 days, the Zacks Consensus Estimate has changed +1.5%.
Harmony Biosciences has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.